A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis (NCT06136741)
Nektar 23-358-05
This trial is No longer recruiting
Registration number NCT06136741
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Dermatology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Johannes S Kern
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR